Ulrike Setinek

Wiener Krankenanstaltenverbund — Austria

Medicine · Health Sciences

19h-index1.3kcitations68works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(28), Fibroblast Growth Factor Research(17), Lung Cancer Research Studies(14), Occupational and environmental lung diseases(11), Lung Cancer Diagnosis and Treatment(9)

Publications68 total

23P Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Immuno-Oncology Technology·2024· 1 citedOpen Access
Supplementary Fig. S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Data from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Data from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Supplementary Table S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Supplementary Table S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Supplementary Fig. S1 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Supplementary Table S2 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Supplementary Table S2 from Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
2023Open Access
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
Journal of Clinical Medicine·2022· 7 citedOpen Access
Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients
Cancers·2022· 6 citedOpen Access
Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
Biomolecules·2021· 13 citedOpen Access
Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature
European Respiratory Review·2021· 34 citedOpen Access
Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
Pharmaceuticals·2020· 28 citedOpen Access
EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
Translational Lung Cancer Research·2020· 28 citedOpen Access
The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers
memo - Magazine of European Medical Oncology·2020· 7 cited
Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion–Positive Metastatic Lung Cancer
Clinical Lung Cancer·2019· 4 cited
Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Annals of Oncology·2019· 1 citedOpen Access
P2.14-46 Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
Journal of Thoracic Oncology·2019Open Access
Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines
Anti-Cancer Drugs·2019· 11 cited
page 1 of 4Next →

Frequent Co-authors

Maximilian J. Hochmair(20), Martin Filipits(14), Walter Berger(13), Stefan Watzka(12), Otto C. Burghuber(11), M. Micksche(9), Michael Grusch(9), Arschang Valipour(9), Dagmar Krenbek(8), Anna Buder(7), Peter Errhalt(7), Gudrun Absenger(7), Robert Pirker(7), Bettina Grasl‐Kraupp(6), Brigitte Marian(6), Heidelinde Cantonati(5), Gerhard Dekan(5), Klaus Holzmann(5), Mir Alireza Hoda(5), Bahil Ghanim(5)